iMDx posts Q2 loss as FDA review of GraftAssureDx continues

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to iMDx posts Q2 loss as FDA review of GraftAssureDx continues

IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

August 10, 2026 4:05 PM EDT

Discussions with FDA advance toward expected marketing authorization for GraftAssureDxFDA completes current portion of substantive review in a timely mannerFavorable Medicare reimbursement policy issued in July significantly increases GraftAssureDx surveillance testing opportunityStrong head-to-head data drive kitted customer interest

NASHVILLE, Tenn., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its first quarter results:

Fellow... More